Buno, KOSDAQ listing public offering price of 21,000 won confirmed

With a competition rate of 1,457 to 1 in demand forecasting, Buno has successfully completed demand forecasting, receiving high attention from domestic and foreign institutional investors.

As a result of forecasting demand for domestic and foreign institutional investors from the 8th to the 9th, the global medical artificial intelligence leading company, VUNO, confirmed the offering price to 21,000 won, which exceeded the top of the desired offering price (15,000 won to 19,500 won). It was revealed on the 15th. As a result, Buno is offering a total of 37.8 billion won through this IPO.

In this demand forecast, a total of 1,548 institutional investors participated, recording a competition rate of 1,457 to 1, and more than 95.4% of institutional investors who participated in the demand forecast presented prices above the top of the public offering band. Among them, 1,426 (92.1%) institutions that offered a final public offering price of 21,000 won or more, and 314 institutions participated in overseas institutions, showing the results of demand forecasting that succeeded as a medical artificial intelligence company attracting attention overseas.

“The majority of domestic institutional investors who participated in the demand forecasting highly appreciated the technology that independently developed and commercialized artificial intelligence solutions applicable to various medical fields based on their own deep learning engines.” It gave a premium to the differentiated competitiveness of Buno.”

As a medical artificial intelligence solution developer, VUNO has successfully commercialized 8 types of optimal medical artificial intelligence solutions based on its original technology and its own deep learning engine VUNO Net. In addition, it has a pipeline that includes diagnosis, treatment, and prognosis prediction by analyzing various medical data such as medical images, pathology, vital signs, and medical voices.The technology and clinical capabilities of our solutions are held in global deep learning challenges and global clinical journals and conferences. It has proven effective and safe.

Buno is effectively selling its own medical artificial intelligence solutions by pioneering a business model optimized for software medical devices such as a pay-per-use billing policy, and is working with various medical companies with a solid distribution network in the domestic and overseas medical markets. Through the partnership of the company, we are strengthening sales synergy and speeding up market settlement.

Through this IPO, Buno plans to expand its strategic partnerships with leading global companies to strengthen domestic and overseas marketing activities for ViewnoMed solutions. In addition, it plans to actively expand domestic and overseas business areas by expanding the product pipeline including pathology and bio-signals currently in clinical trials as well as medical imaging.

Mr. Hyun-Joon Kim, CEO of Vuno, said, “I sincerely thank the investors of domestic and foreign institutions who have positively evaluated Vuno’s unrivaled artificial intelligence technology and future growth potential.” I will show you how to go ahead.”

FINTECHPOST